A Bispecific Breakthrough: Addressing Real Clinician Questions on the Practical Application of Bispecific Antibodies Across Practice Settings in Multiple Myeloma

Program Description

The introduction of bispecific antibodies (BsAbs) into the relapsed/refractory multiple myeloma (RRMM) landscape represents a monumental shift in the treatment of this generally incurable disease. However, BsAbs also unlock a host of new challenges for clinicians and significantly adjust practice norms. Additionally, several important questions lack definitive answers, such as the optimal positioning and sequencing of these agents in practice. Fortunately, increasing data are accumulating from randomized clinical trials to help address these unknowns, and real-world data (RWD) are helping to evaluate important factors that are not practical, feasible, or ethical to address within clinical trials, helping to contextualize the impact of BsAbs across diverse care settings. 

This unique intervention isolates the primary clinical needs of practicing clinicians related to developments in BsAbs and directly addresses the most pressing questions of community-based hematologic oncologists surrounding their integration across diverse care settings. Join MM experts Drs Caitlin Costello, Ajai Chari, and Saad Usmani as they use the voices of your peers to evaluate clinical data in conjunction with RWD to provide valuable insights on how BsAbs affect patients’ lives and pinpoint barriers to their effective use. 

Target Audience

The target audience for this activity includes medical and hematologic oncologists, advanced practice professionals (APPs), and pharmacists working in cancer care settings. 

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Identify patients with RRMM who are eligible for targeted BsAbs to individualize therapeutic selection appropriately.
  • Utilize the results of controlled clinical trials   and RWD with BsAbs in patients with RRMM to effectively implement these agents across clinical practice settings. 
  • Discuss mitigation strategies for adverse events to ensure safe and continuous treatment for patients with RRMM who are prescribed targeted BsAbs.
  • Employ practices aimed at the unique logistic challenges associated with the use of BsAbs for RRMM to address access barriers in community-based settings.
Course summary
Available credit: 
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Course opens: 
01/31/2025
Course expires: 
01/31/2026
Cost:
$0.00
Rating: 
0

   Caitlin Costello, MD (Moderator & Chair) 
   Clinical Professor of Medicine
   Director, Multiple Myeloma Program
   Division of Blood and Marrow Transplantation
   Moores Cancer Center UC San Diego 
   La Jolla, CA

   Ajai Chari, MD (Panelist)
   Director of Multiple Myeloma Program
   Professor of Clinical Medicine
   University of California
   San Francisco, CA

 

   Saad Usmani, MD, MBA, FACP (Panelist)
   Chief of Myeloma Service
   Member, Memorial Sloan Kettering Cancer Center, New York, NY 
   Attending Physician, Myeloma, Cellular Therapy and Adult BMT
   Professor, Weill Cornell Medical College, Cornell University
   New York, NY

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.

    

Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

PHYSICIAN CREDIT
Purdue University designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PHARMACISTS
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This is a  knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-25-003-H01-P, 0.75 contact hours (0.75 CEU).
 
ADVANCED PRACTICE PROFESSIONALS
The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME. Additionally, the American Academy of Physician Assistants (PAs) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from providers accredited by the ACCME. As a result, NPs and PAs will be included as a target audience.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the live activity enabling participants to register their credit with the appropriate licensing boards or associations.

Disclosure of Relevant Financial Relationships

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Faculty Disclosures

Dr Chari reported the following financial relationships:

  • Consulting Fees: AbbVie Inc.; Adaptive Biotechnologies; Amgen Inc.; Antigen Express ; Bristol Myers Squibb; Forum Pharmaceuticals Inc.; Genentech; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics Inc.; Sanofi/Genzyme Corporation; Takeda Pharmaceuticals North America, Inc.
  • Grants/Research Support:  Janssen Pharmaceuticals, Inc.

Dr Costello reported the following financial relationships:

  • Consulting Fees: AstraZeneca; Bristol Myers Squibb Company; Genentech; Janssen Biotech, Inc.; Karyopharm Therapeutics; Pfizer, Inc.

Dr Usmani reported the following relationships: 

  • Advisory Board: AstraZeneca 
  • Grants/Research Support: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Gracell Therapeutics; Janssen Biotech, Inc.; Merck; Sanofi

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation 


There are no fees for participating in and receiving credit for this activity. During the period January 31, 2025, through January 31, 2026, participants must: 1) review the learning objectives and faculty disclosures; 2) complete the pre-activity assessment; 3) watch the educational activity and respond to the intra-program polling questions; 4) complete the posttest by recording the best answer to each question; and 5) complete the evaluation form.

Commercial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Available Credit

  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance

Price

Cost:
$0.00
Please login or register to take this course.